Lesson 15 — Pleurodesis for Malignant Pleural Effusion: The Optimal Agent and
Methodology
By Marc M. P. Noppen, MD, PhD, FCCP
Read/Print This Document
Poststudy Questions
Dr. Noppen is Associate Professor, University Hospital, Brussels, Belgium.
Dr. Noppen has disclosed no significant relationships with the companies/organizations
whose products or services may be discussed within this chapter.
Lesson 16 — α1-Antitrypsin Augmentation: Approaches and Benefits
By Robert A. Sandhaus, MD, PhD, FCCP
Read/Print This Document
Poststudy Questions
Dr. Sandhaus is Professor of Medicine and Director, Alpha-1 Antitrypsin Deficiency Program,
National Jewish Health, Denver, CO. He is also Executive Vice President and Medical Director,
AlphaNet; Medical Director, Alpha-1 Foundation, Miami, FL.
Dr. Sandhaus has disclosed significant relationships with the following companies/organizations
whose products or services may be discussed within this chapter:
University grant monies – Salary grant from National Jewish Health, funded by the
Alpha-1 Foundation
Grant monies – In addition to the above, funds have been received from the National Institutes of
Health for the performance of clinical trials related to α1-antitrypsin deficiency.
Consultant fee – Kamada, GTC, Talecris, CSL Behring, Dey, Arriva. Consultant fees are
donated to the Alpha-1 Foundation and AlphaNet.
Speaker bureau – Dey Pharmaceuticals
Advisory committee – Arriva
Fiduciary position – Member, Board of Directors of AlphaNet, Association for the Accreditation
of Human Research Protection Programs, Osteogenesis Imperfecta Foundation. Executive Vice
President and Medical Director, AlphaNet; Medical Director, Alpha-1 Foundation
All fees or honoraria are donated to the Alpha-1 Foundation or AlphaNet (both are not-for-profit
organizations serving the Alpha-1 community).
